IP Library Granted Patent US 9,034,881
Granted Patent B2
US 9,034,881 · App. 14/025,609 · Granted May 19, 2015

Treatment for vitiligo

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,034,881
App. No.
14/025,609
Granted
May 19, 2015
Kind
B2
Abstract

Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.

Claims (16)

1. A method of treating vitiligo, comprising administering to a subject a therapeutically effective amount of a compound of formula I, formula II, or both

2. The method of claim 1 , wherein the compound is in the form of a pharmaceutically acceptable salt.

3. The method of claim 1 , wherein the subject is identified as having vitiligo.

4. The method of claim 1 , wherein the subject is identified as being at risk of developing vitiligo.

5. The method of claim 1 , wherein the therapeutically effective amount ranges from about 0.0001 mg/kg/day to about 100 mg/kg/day.

6. The method of claim 1 , wherein the compound is administered as a topical formulation comprising from 0.0001 to 10% (w/w) of the compound of formula I and/or II.

7. The method of claim 1 , wherein the subject has one or more depigmented skin areas, and the compound is applied topically to at least one of the depigmented skin areas.

8. The method of claim 7 , wherein the compound is also administered systemically to the subject.

9. The method of claim 1 , wherein the compound is administered systemically to the subject.

10. The method of claim 1 , wherein the subject has vitiligo of the eye, and the compound is administered ocularly to the subject to treat the vitiligo.

11. The method of claim 1 , wherein the compound is a salt of compound II.

12. The method of claim 11 , wherein the salt of compound II is selected from a sodium salt, a potassium salt, a calcium salt, an arginine salt, choline salt, and combinations thereof.

13. The method of claim 1 , wherein the compound is administered either in combination or adjunctively with a second therapeutic.

14. The method of claim 13 , wherein the second therapeutic is an anti-inflammatory, an antihistamine, an antibiotic, an antiviral medication, systemic phototherapy, psoralen photochemotherapy, excimer laser therapy, thyroid hormone replacement medication, or any combination thereof.

15. The method of claim 13 , wherein the second therapeutic comprises benzoyl peroxide, coal tar, vitamin A, salicylic acid, tacrolimus, pimecrolimus, psoralen, 5-methylpsoralen, 8-methoxypsoralen, trimethylpsoralen, prednisone, methylprednisolone, prednisolone, erythromycin, tetracycline, dicloxacillin, ketoconazole, acyclovir, azathioprine, methotrexate, mycophenolate, mercaptopurine, cyclophosphamide, cyclosporine, sirolimus, mycophenolate, mycophenolate mofetil, azathioprine, antilymphocyte globulin (ALG), antithymocyte globulin (ATG), monoclonal anti-T-cell antibodies (OKT3), calcipotriol, tacalcitol, sulfacetamide, gentamicin, tobramycin, ciprofloxacin, ofloxacin, fluorometholone, dexamethasone, ibuprofen, diclofenac, ketorolac, flurbiprofen, livostin, patanol, cromolyn, alomide, pheniramine, triflurthymidine, adenine, arabinoside, idoxuridine, timolol, metipranolol, carteolol, betaxolol, levobunolol, latanoprost, pilocarpine, carbachol, bromonidine, iopidine, dorzolamide, epinephrine, dipivefrin, clobetasol propionate, betamethasone dipropionate, halobetasol proprionate, diflorasone diacetate, fluocinonide, halcinoide, amcinonide, desoximetasone, triamcinolone acetonide, mometasone furoate, fluticasone propionate, fluocinolone acetonide, fluticasone propionate, hydrocortisone valerate, hydrocortisone butyrate, flurandrenolide, desonide, prednicarbate, hydrocortisone, emedastine, azelastine, tetrahydrozoline hydrochloride, naphazoline, nepafenac, loteprednol, azelastie, cromal, ketotifen, Iodoxamine, nedocromil, olopatadine, pemirolast, monofloxacin, trifluridine, or combinations thereof.

16. The method of claim 13 , wherein the second therapeutic comprises sulfacetamide, erythromycin, gentamicin, tobramycin, ciprofloxacin, ofloxacin, prednisolone, fluorometholone, dexamethasone, ibuprofen, diclofenac, ketorolac, flurbiprofen, livostin, patanol, cromolyn, alomide, pheniramine, triflurthymidine, adenine, arabinoside, idoxuridine, timolol, metipranolol, carteolol, betaxolol, levobunolol, latanoprost, pilocarpine, carbachol, bromonidine, iopidine, dorzolamide, epinephrine, dipivefrin or combinations thereof.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2013
From: MAGILAVY, DANIEL
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 031402/0146 →